PAP
LGND icon

Persistent Asset Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Persistent Asset Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-791
Closed -$150K – 412
2025
Q4 		$150K Buy
+791
New +$152K 0.07% 244

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Persistent Asset Partners's LGND Position: Q1 2026 in Review

Persistent Asset Partners sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 791 shares — an estimated $150K sold.

Persistent Asset Partners first reported a position in LGND in Q4 2025 and held it in 1 quarter. The position peaked at $150K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Persistent Asset Partners reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 791 Ligand Pharmaceuticals shares in Q1 2026, an estimated $150K.
  • Persistent Asset Partners first reported a position in Ligand Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Ligand Pharmaceuticals position peaked at $150K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.